Characterizing the Upper Airway Manifestations in Primary Ciliary Dyskinesia and Primary Immunodeficiencies
Public ClinicalTrials.gov record NCT04919018. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Though common, morbidities related to upper airway disease in primary ciliary dyskinesia (PCD) and primary immunodeficiencies (PID) have not been fully characterized. These conditions can be difficult to distinguish due to their overlapping phenotypes. The sinonasal and middle ear features are often identified as most problematic by patients and their families, and optimal, highly effective treatment regimens have not been established. The main objective of this project is to characterize and compare the upper airway phenotypes in individuals with confirmed diagnosis of PCD and PID, and to collect critical data to inform the design of future clinical trials of treatment of the upper airway diseases. The investigators anticipate that these investigations will discern the clinical, anatomical, and pathophysiological phenotypes of paranasal sinus disease in PCD and PID, identifying disease endpoints and biomarkers that differentiate these two overlapping disorders. Findings from these studies will also enhance our understanding of middle ear disease and associated hearing loss in a cross-sectional cohort of patients with PCD and PID. Ultimately, the long-term goal of our Consortium is to elucidate underlying phenotypes and genotypes of these diseases, potentially leading to novel therapeutics that will improve the lives of affected individuals. Given the COVID pandemic, certain procedures will have the option to be converted to telehealth visits to ensure compliance with local guidelines and participant safety.
Study identification
- NCT ID
- NCT04919018
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 159 participants
Conditions and interventions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 5 Years to 45 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2021
- Primary completion
- Jul 22, 2025
- Completion
- Jul 22, 2025
- Last update posted
- Aug 20, 2025
2021 – 2025
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Washington University in St. Louis | St Louis | Missouri | 63130 | — |
| University of North Carolina at Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
Recently updated Primary Ciliary Dyskinesia trials
Other public records listing Primary Ciliary Dyskinesia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07699302: Clearance in Primary Ciliary Dyskinesia Not yet recruiting
- NCT07288827: Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia Recruiting
- NCT05889013: Utility of PCD Diagnostics to Improve Clinical Care Recruiting
- NCT03704207: Utility of PCD Diagnostics to Improve Clinical Care Recruiting
- NCT06172374: A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials Active, not recruiting
- NCT05287022: Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04919018, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 20, 2025 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04919018 live on ClinicalTrials.gov.